BR112021021244A2 - Inibidores glicomiméticos multiméricos ligados à galactose de receptores de e-selectinas, galectina-3 e/ou quimiocina cxcr4 - Google Patents
Inibidores glicomiméticos multiméricos ligados à galactose de receptores de e-selectinas, galectina-3 e/ou quimiocina cxcr4Info
- Publication number
- BR112021021244A2 BR112021021244A2 BR112021021244A BR112021021244A BR112021021244A2 BR 112021021244 A2 BR112021021244 A2 BR 112021021244A2 BR 112021021244 A BR112021021244 A BR 112021021244A BR 112021021244 A BR112021021244 A BR 112021021244A BR 112021021244 A2 BR112021021244 A2 BR 112021021244A2
- Authority
- BR
- Brazil
- Prior art keywords
- galectin
- selectin
- cxcr4 chemokine
- galactose
- chemokine receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838206P | 2019-04-24 | 2019-04-24 | |
| PCT/US2020/029066 WO2020219417A1 (en) | 2019-04-24 | 2020-04-21 | Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021021244A2 true BR112021021244A2 (pt) | 2021-12-21 |
Family
ID=70680623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021244A BR112021021244A2 (pt) | 2019-04-24 | 2020-04-21 | Inibidores glicomiméticos multiméricos ligados à galactose de receptores de e-selectinas, galectina-3 e/ou quimiocina cxcr4 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230079833A1 (https=) |
| EP (1) | EP3958978A1 (https=) |
| JP (1) | JP2022529806A (https=) |
| KR (1) | KR20220012246A (https=) |
| CN (1) | CN114340736A (https=) |
| AU (1) | AU2020263266A1 (https=) |
| BR (1) | BR112021021244A2 (https=) |
| CA (1) | CA3136661A1 (https=) |
| WO (1) | WO2020219417A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3122321A1 (en) | 2018-12-27 | 2020-07-02 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycosides |
| ES3063748T3 (en) * | 2019-07-31 | 2026-04-20 | Crescent Biopharma Inc | E-selectin antagonists for use in enhancing the survival of reconstituted, bone marrow-depleted hosts |
| US20230147312A1 (en) | 2020-03-27 | 2023-05-11 | Glycomimetics, Inc. | Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin |
| WO2021247396A1 (en) | 2020-05-31 | 2021-12-09 | Magnani John L | Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis |
| AU2021292458A1 (en) | 2020-06-14 | 2023-01-19 | GlycoMimetics | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
| US20240269157A1 (en) | 2021-08-03 | 2024-08-15 | Glycomimetics, Inc. | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097658A2 (en) | 2002-05-16 | 2003-11-27 | Glycomimetics, Inc. | Compounds and methods for inhibiting selectin-mediated function |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| PL2264043T3 (pl) | 2005-09-02 | 2018-04-30 | Glycomimetics, Inc. | Heterobifunkcyjne inhibitory pan-selektyny |
| EP2074132B1 (en) | 2006-10-12 | 2013-05-15 | GlycoMimetics, Inc. | Glycomimetic replacements for hexoses and n-acetyl hexosamines |
| ES2543063T3 (es) | 2008-05-16 | 2015-08-14 | Galecto Biotech Ab | Nueva síntesis de inhibidores de galactósidos |
| KR102055958B1 (ko) | 2011-12-22 | 2019-12-13 | 글리코미메틱스, 인크. | E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법 |
| CA2888527A1 (en) * | 2012-10-31 | 2014-05-08 | Glycomimetics, Inc. | E-selectin antagonists compounds and methods of use |
| JP6689854B2 (ja) | 2014-12-03 | 2020-04-28 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 |
| AU2017341065B2 (en) * | 2016-10-07 | 2023-04-06 | Crescent Biopharma, Inc. | Highly potent multimeric E-selectin antagonists |
-
2020
- 2020-04-21 JP JP2021562811A patent/JP2022529806A/ja active Pending
- 2020-04-21 CA CA3136661A patent/CA3136661A1/en active Pending
- 2020-04-21 US US17/605,107 patent/US20230079833A1/en not_active Abandoned
- 2020-04-21 WO PCT/US2020/029066 patent/WO2020219417A1/en not_active Ceased
- 2020-04-21 CN CN202080046293.0A patent/CN114340736A/zh active Pending
- 2020-04-21 AU AU2020263266A patent/AU2020263266A1/en not_active Abandoned
- 2020-04-21 BR BR112021021244A patent/BR112021021244A2/pt unknown
- 2020-04-21 KR KR1020217037835A patent/KR20220012246A/ko not_active Abandoned
- 2020-04-21 EP EP20725311.3A patent/EP3958978A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022529806A (ja) | 2022-06-24 |
| KR20220012246A (ko) | 2022-02-03 |
| EP3958978A1 (en) | 2022-03-02 |
| CA3136661A1 (en) | 2020-10-29 |
| US20230079833A1 (en) | 2023-03-16 |
| CN114340736A (zh) | 2022-04-12 |
| WO2020219417A1 (en) | 2020-10-29 |
| AU2020263266A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021021244A2 (pt) | Inibidores glicomiméticos multiméricos ligados à galactose de receptores de e-selectinas, galectina-3 e/ou quimiocina cxcr4 | |
| EA202190377A1 (ru) | Композиции ингибиторов cxcr4 и способы получения и применения | |
| MX2025007468A (es) | Composiciones y metodos para el manejo de trastornos | |
| MX2020011562A (es) | Agonistas del receptor de la hormona tiroidea y usos de los mismos. | |
| BR112021025537A2 (pt) | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
| MX2024000349A (es) | Compuestos y usos de los mismos. | |
| BR112022000328A2 (pt) | Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
| BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
| BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
| UY31619A1 (es) | Compuestos espiro como antagonistas del receptor npy y5 | |
| CL2024002614A1 (es) | Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso. | |
| BR112022010411A2 (pt) | Composições bacterianas projetadas e usos das mesmas | |
| BR112022017822A2 (pt) | Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas | |
| BR112021009078A8 (pt) | Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos | |
| BR112021018262A2 (pt) | Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina | |
| UY39522A (es) | Anticuerpos de cadena pesada que se unen al receptor alfa de folato | |
| BR112023021225A2 (pt) | Anticorpos anti-cd20 e estruturas t car | |
| BR112022004461A2 (pt) | Conjugado de galnac-oligonucleotídeo para entrega ao fígado e método de fabricação do mesmo | |
| CL2018003044A1 (es) | 6-aminopiridina-3-yl tiazoles como moduladores de ror. | |
| BR112018008839A2 (pt) | métodos e composições para o tratamento da amiloidose | |
| WO2024227174A3 (en) | Antibodies that bind ox40l and methods of use | |
| CL2024000370A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |